Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Xiaowei Wei
- Phone Number: 025-52271000
- Email: gswxw@126.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Advanced/metastatic solid tumors other than primary lung cancer
- Alk-positive or MET14 exon skipping mutation by IHC\FISH\NGS\RT-PCR
- Have no standard treatment after MDT discussion, or could not tolerate the standard treatment, or the patient refused the standard treatment
- Adequate liver and kidney function
- Adequate bone marrow function
- ECOG PS 0-3
- Female subjects should not be pregnant. All human subjects should able to comply with the required protocol and follow-up procedures, and able to receive oral medications Written informed consent provided
Exclusion Criteria:
- Active viral, bacterial, or fungal infection detected 2 weeks before enrollment
- Pregnancy or lactation
- receiving medications or herbal supplements with potent inducers of CYP3A4 (at least 3 weeks prior)
- Any severe or uncontrolled systemic illness, including uncontrolled Hypertension and active bleeding, any nonadherence that the investigator considered to be detrimental to study participation or adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV)
- Ineligible cardiac function
- Interstitial lung disease, drug-induced interstitial lung disease, previous history of radiation pneumonitis requiring steroid therapy, or any evidence of active interstitial lung disease
- Lack of adequate bone marrow reserve or organ function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ensartinib
|
ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
progression-free survival
Time Frame: 2 years
|
time to progression or Intolerable toxicity occurred
|
2 years
|
|
Overall responce rate
Time Frame: 1year
|
Proportion of patients with CR/PR response in the total population
|
1year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease control rate
Time Frame: 1year
|
Proportion of patients with CR/PR/SD response in the total population
|
1year
|
|
Overall survival
Time Frame: 3 years
|
time to death
|
3 years
|
|
Duration of responce
Time Frame: 3 years
|
time from first assessment of CR or PR to the first assessment of PD or death
|
3 years
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: 3 years
|
The safety of Ensartinib treatment will be assessed according to CTCAE v5.0 criteria observed over the whole treatment period.
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BD-EN-IV018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.